Contacts

Tremendous success for MedinCell’s €30 million capital increase for qualified investors

February 11, 2021

Offer widely oversubscribed: 2.5 times the total amount of the capital increase
Strong support from French and international leading shareholders and investors


MedinCell (FR0004065605 – MEDCL), a clinical stage pharmaceutical company developing a portfolio of long-acting injectable products in various therapeutic areas (the “Company”), is today announcing the successful completion of its €29.8 million capital increase via a placement with French and international qualified investors through an accelerated bookbuilding process (the “Offering”).

Bryan, Garnier & Co. Limited1 and ODDO BHF SCA are acting as Joint Global Coordinators and Joint Bookrunners.

Session en français

Rendez-vous le lundi 5 septembre à 18h30 (CEST) pour une vidéoconférence dédiée à la présentation des résolution de l'Assemblée Générale

English session

On Monday 5, September at 6.30 pm (CEST) participate in our videoconference dedicated to the presentation of the resolutions of the General meeting

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.